QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- N/A
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
- Status
- COMPLETED
- Phase
- PHASE2
Cetuximab Monotherapy Maintenance Treatment in mCRC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
- Status
- COMPLETED
- Phase
- PHASE1
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
- Status
- COMPLETED
- Phase
- PHASE3
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab
- Status
- COMPLETED
- Phase
- PHASE1
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2